Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
Delayed Swiss Exchange  -  11:31 2022-11-29 am EST
48.30 CHF   +0.21%
11/24Basilea Pharmaceutica : Updated November 24, 2022
PU
11/02Basilea To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-Seven Therapeutics
MT
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Basilea Pharmaceutica Secures $78 Million Senior Secured Loan From Athyrium Capital

09/21/2022 | 01:43am EST


ę MT Newswires 2022
All news about BASILEA PHARMACEUTICA AG
11/24Basilea Pharmaceutica : Updated November 24, 2022
PU
11/02Basilea To Sell Preclinical CLK Kinase Inhibitors To Twentyeight-Seven Therapeutics
MT
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutic..
GL
11/02Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutic..
DJ
10/26Basilea Pharmaceutica : Updated October 26, 2022
PU
10/24Basilea to Submit New Drug Application for Bloodstream Infection Drug Ceftobiprole in 2..
MT
10/24ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the tre..
GL
10/24ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the tre..
AQ
10/24Basilea : ERADICATE phase 3 study results highlight the potential role of ceftob..
DJ
10/24Basilea Pharmaceutica AG 's ERADICATE Phase 3 Study Results Highlight the Potential Rol..
CI
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2022 115 M 121 M 121 M
Net income 2022 -21,3 M -22,3 M -22,3 M
Net Debt 2022 98,1 M 103 M 103 M
P/E ratio 2022 -26,3x
Yield 2022 -
Capitalization 574 M 603 M 603 M
EV / Sales 2022 5,84x
EV / Sales 2023 4,69x
Nbr of Employees 177
Free-Float 88,1%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 48,30 CHF
Average target price 68,58 CHF
Spread / Average Target 42,0%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG17.79%605
MODERNA, INC.-30.95%67 378
IQVIA HOLDINGS INC.-23.99%39 832
LONZA GROUP AG-34.32%39 180
ALNYLAM PHARMACEUTICALS, INC.23.36%25 738
SEAGEN INC.-21.59%22 506